Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 531

1.

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.

Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, Machón M, Marcos-Gragera R.

Gynecol Oncol. 2013 Sep;130(3):609-14. doi: 10.1016/j.ygyno.2013.05.039.

PMID:
23747837
2.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

3.
4.

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Bauer K, Parise C, Caggiano V.

BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.

5.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059.

PMID:
23240985
6.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
7.

[Survival of patients with metastatic breast cancer according to pathological types of tumors].

Sánchez R C, Acevedo C F, Petric G M, Galindo A H, Domínguez C F, León R A, Razmilic V D, Ceballos C, Espinoza F, Navarro O ME, Oddó B D, Camus A M.

Rev Med Chil. 2014 Apr;142(4):428-35. doi: 10.4067/S0034-98872014000400003. Spanish.

8.

Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.

Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.

PMID:
23040002
9.

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.

Breast Cancer Res Treat. 2009 Jan;113(2):357-70. doi: 10.1007/s10549-008-9926-3.

PMID:
18324472
10.

Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.

Luyeye Mvila G, Batalansi D, Praet M, Marchal G, Laenen A, Christiaens MR, Brouckaert O, Ali-Risasi C, Neven P, Van Ongeval C.

Breast. 2015 Oct;24(5):642-8. doi: 10.1016/j.breast.2015.07.031.

PMID:
26279132
11.

Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW.

Cancer. 2010 Jun 1;116(11):2549-59. doi: 10.1002/cncr.25016.

12.
13.

Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.

BMC Cancer. 2010 May 21;10:223. doi: 10.1186/1471-2407-10-223.

14.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
15.

Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.

Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B.

J BUON. 2015 Jan-Feb;20(1):28-34.

PMID:
25778292
16.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

PMID:
24065473
17.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840
18.

Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.

Parise C, Caggiano V.

Cancer Epidemiol. 2014 Oct;38(5):556-62. doi: 10.1016/j.canep.2014.08.001.

PMID:
25172158
19.

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.

Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F.

Virchows Arch. 2010 Oct;457(4):467-76. doi: 10.1007/s00428-010-0964-y.

PMID:
20809337
20.

Age related influence of triple receptor status on metastatic breast cancer post relapse survival.

Todorovic-Rakovic N, Neskovic-Konstantinovic Z.

J BUON. 2013 Oct-Dec;18(4):851-8.

PMID:
24344008
Items per page

Supplemental Content

Support Center